company background image

Cann Global ASX:CGB Stock Report

Last Price


Market Cap







25 May, 2022


Company Financials
CGB fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

CGB Stock Overview

Cann Global Limited operates in medicinal cannabis and hemp food industries in Australia and internationally.

Cann Global Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cann Global
Historical stock prices
Current Share PriceAU$0.024
52 Week HighAU$0.15
52 Week LowAU$0.024
1 Month Change-27.27%
3 Month Change-20.00%
1 Year Change-82.55%
3 Year Changen/a
5 Year Change-92.62%
Change since IPO-99.54%

Recent News & Updates

Jan 16
What Can We Make Of Cann Global's (ASX:CGB) CEO Compensation?

What Can We Make Of Cann Global's (ASX:CGB) CEO Compensation?

Sholom Feldman became the CEO of Cann Global Limited ( ASX:CGB ) in 2007, and we think it's a good time to look at the...

Shareholder Returns

CGBAU PharmaceuticalsAU Market

Return vs Industry: CGB underperformed the Australian Pharmaceuticals industry which returned -17.9% over the past year.

Return vs Market: CGB underperformed the Australian Market which returned -0% over the past year.

Price Volatility

Is CGB's price volatile compared to industry and market?
CGB volatility
CGB Average Weekly Movement16.4%
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement9.3%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market4.2%

Stable Share Price: CGB is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: CGB's weekly volatility has decreased from 30% to 16% over the past year, but is still higher than 75% of Australian stocks.

About the Company

2007n/aSholom Feldman

Cann Global Limited operates in medicinal cannabis and hemp food industries in Australia and internationally. The company operates through Hemp and Medical Cannabis Products, and Mining Exploration and Evaluation segments. It grows and cultivates hemp and medical cannabis products; and provides plant-based food and skincare products.

Cann Global Fundamentals Summary

How do Cann Global's earnings and revenue compare to its market cap?
CGB fundamental statistics
Market CapAU$6.21m
Earnings (TTM)-AU$4.97m
Revenue (TTM)AU$980.09k


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CGB income statement (TTM)
Cost of RevenueAU$752.05k
Gross ProfitAU$228.03k
Other ExpensesAU$5.19m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)-0.019
Gross Margin23.27%
Net Profit Margin-506.61%
Debt/Equity Ratio0.7%

How did CGB perform over the long term?

See historical performance and comparison
New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Cann Global forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cann Global has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Cann Global performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CGB is currently unprofitable.

Growing Profit Margin: CGB is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CGB is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.

Accelerating Growth: Unable to compare CGB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CGB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.9%).

Return on Equity

High ROE: CGB has a negative Return on Equity (-32.93%), as it is currently unprofitable.

Financial Health

How is Cann Global's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CGB's short term assets (A$11.2M) exceed its short term liabilities (A$3.1M).

Long Term Liabilities: CGB's short term assets (A$11.2M) exceed its long term liabilities (A$560.2K).

Debt to Equity History and Analysis

Debt Level: CGB has more cash than its total debt.

Reducing Debt: CGB's debt to equity ratio has reduced from 0.8% to 0.7% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CGB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CGB has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 11.8% each year.


What is Cann Global current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CGB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CGB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CGB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CGB's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CGB has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Sholom Feldman (45 yo)





Mr. Sholom Dovber Feldman serves as the Chief Executive Officer of Cann Global Limited (formerly Queensland Bauxite Limited) (Formerly, Australian Gold Investments Limited) since 2007 and serves as its Man...

CEO Compensation Analysis

Compensation vs Market: Sholom's total compensation ($USD220.56K) is about average for companies of similar size in the Australian market ($USD291.26K).

Compensation vs Earnings: Sholom's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: CGB's management team is considered experienced (2.8 years average tenure).

Board Members

Experienced Board: CGB's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.2%.

Top Shareholders

Company Information

Cann Global Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Cann Global Limited
  • Ticker: CGB
  • Exchange: ASX
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$6.213m
  • Shares outstanding: 258.87m
  • Website:


  • Cann Global Limited
  • 133 Castlereagh Street
  • Level 21
  • Sydney
  • New South Wales
  • 2000
  • Australia


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Annual Earnings2021/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.